RhIG Workup in a Weak D Prenatal Patient
A 29-year-old G2P1 woman at 26 weeks presents for routine prenatal care. Her ABO is A, and her antibody screen is negative. Her tube typing shows a 1+ reaction with anti-D at immediate spin that persists at antihuman globulin but is weaker than the reagent control, and she does not react with a monoclonal anti-D blend in a different clone set. She received RhIG at 28 weeks in her prior pregnancy and delivered an Rh-positive infant 18 months ago without postpartum RhIG documentation. Her physician asks whether she needs RhIG now and whether the weak reaction should change management. The laboratory has no molecular genotyping onsite and sends out testing with a 7-10 day turnaround.
1. How should the laboratory classify this D typing result, and what are the immediate implications for RhIG administration at 26 weeks?
Read the worked answer
The result is a weak/variant D, not a straightforward D-positive or D-negative. Key reasoning:
- Distinguish weak D from partial D and from passive anti-D. The prior RhIG 18 months ago is too remote to produce passive anti-D at 1+ persisting at AHG; passive anti-D from antenatal RhIG given in the prior pregnancy would be gone. A weak reaction pattern that differs by clone set suggests a quantitative weak D or a partial D.
- Do not simply call D-negative. A weak D type 1-3 patient is generally managed as D-positive for RhIG purposes and does not require RhIG; a partial D patient should be managed as D-negative and should receive RhIG because she can form anti-D against epitopes she lacks.
- Immediate practical answer: Because genotyping is pending and she is at 26 weeks, the safe approach is to administer RhIG now (standard antenatal prophylaxis at ~28 weeks can be given at this visit) while pursuing genotyping. Giving RhIG to a true weak D type 1-3 is not harmful; withholding it from a partial D is harmful.
- Document and follow up: Send molecular RHD genotyping, note the discrepancy in the record, and use the genotype to guide postpartum management and any future transfusion (weak D/partial D patients should receive D-negative RBCs unless genotype proves weak D type 1-3).
2. The send-out returns RHD genotyping showing a partial D (DAR variant). How does this change her postpartum plan if she delivers an Rh-positive infant, and how should any future RBC transfusion be selected?
Read the worked answer
A partial D (DAR) result means she lacks some D epitopes and is at risk for anti-D alloimmunization. Management:
- Treat as D-negative for RhIG. She requires postpartum RhIG if the infant is D-positive (and a fetomaternal hemorrhage [FMH] screen/quantitation, e.g., rosette or flow, to size the dose). Standard dose is 300 µg; if FMH exceeds ~15 mL of D-positive fetal RBCs (30 mL whole blood), additional vials are indicated based on quantitation.
- Antenatal: She should have received RhIG at 28 weeks; confirm documentation.
- Transfusion: She should receive D-negative RBCs for any transfusion, because transfusing D-positive units could immunize her against missing D epitopes.
- Counseling: Note the partial D status in the chart, inform obstetrics, and flag for future pregnancies (RhIG prophylaxis each pregnancy, antibody monitoring).
- Do not use the weak-D-as-positive shortcut - that rule applies only to weak D types 1-3, not partial D variants.